Safety considerations in IGIV utilization

International Immunopharmacology
Jerry Siegel

Abstract

One of the primary patient concerns about IGIV infusions is safety. Patients and physicians are both concerned about transmission of infectious agents and product tolerability. Since the documented transmission of hepatitis C virus in 1994, the manufacturers of IGIV products have added additional steps to remove and/or deactivate viruses. There are numerous different methods employed to accomplish this goal. It is desirable to utilize methods that are separate and additive to decrease the likelihood of viral or prion transmission with the infusion of IGIV products. This article describes the different methods and the impact on enveloped and non-enveloped viruses and prions. IGIV tolerability is impacted by the pharmaceutical differences in these products. Different stabilizers such as sugars, amino acids and sodium chloride affect the osmolality of the products and their potential for adverse events. Patients with co-morbid conditions including age and impaired renal status could require a change in product, concentration and rate of administration.

References

Feb 1, 1993·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J M RomeoG N Vyas
Feb 1, 1993·Archives of Neurology·E TanJ R Mendell
Nov 23, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·UNKNOWN American Society of Health-System Pharmacists (ASHP)

❮ Previous
Next ❯

Citations

Apr 23, 2010·Expert Opinion on Drug Safety·James B CaressKara D Eickman
May 23, 2012·The American Journal of Medicine·Giovanni FerraraMarkus Maeurer
Mar 3, 2009·Journal of the American Academy of Dermatology·Jeanmarie B Rey, Rebecca B Luria
Sep 20, 2015·Autoimmunity Reviews·Patrick CherinJean-François Viallard
Nov 1, 2007·Dermatologic Therapy·Anthony P Fernandez, Francisco A Kerdel
Jul 25, 2012·Global Public Health·Theresa SeetohRichard Coker
Jul 14, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Patrick Chérin, Jean Cabane
May 10, 2006·International Archives of Allergy and Immunology·Arvind KumarM Eric Gershwin
Sep 12, 2015·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·R Ts Bembeeva, N N Zavadenko
Apr 7, 2009·Expert Review of Anti-infective Therapy·Maki YamamotoDavid K Imagawa
Sep 15, 2011·Drugs & Aging·M Jennifer Cheng, Colleen Christmas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.